Search
ProQR Therapeutics NV
PRQRAdd to Watchlist
1.720USD
-0.060-3.37%
Close 07-31 16:00（ET）Quotes delayed by 15 min
228.74MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of ProQR Therapeutics NV is 8.67, ranking 74 out of 385 in the Biotechnology & Medical Research industry. The average price target is 9.50, with a high of 14.00 and a low of 5.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
9.000
Target Price
+423.26%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
ProQR Therapeutics NV
PRQR
9
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is ProQR Therapeutics NV's expected revenue for the next quarter?
ProQR Therapeutics NV's expected revenue is 5.28M.
What is ProQR Therapeutics NV's price target?
Analysts forecast that ProQR Therapeutics NV's price target is USD 9.50, with the highest forecast at USD 14.00 and the lowest forecast at USD 5.00.
How have ProQR Therapeutics NVPRQR's recent earnings per share performed?
The market expectation was USD -0.15, while ProQR Therapeutics NVPRQR's earnings per share (EPS) for the previous quarter was USD -0.10. EPS for the next quarter is expected at USD -0.13.
What is the analyst rating for ProQR Therapeutics NV?
Based on the ratings of ProQR Therapeutics NV's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.